Tuesday, October 6, 2015

Daniel Hoffman

Pharma distorts the facts to keep Medicare from negotiating drug prices

Monday, July 27, 2015, 10:40 AM
In 1967, Richard S. Harris wrote a four-part series for The New Yorker, describing how Medicare came to be enacted. The leading opponent of that legislation was the American Medical Association. The AMA's central argument against this valuable piece of legislation was its contention that government-supported... Read more

Pharma Weakens FDA Oversight as the Price of Letting Congress Increase NIH Funding

Monday, July 13, 2015, 3:03 PM
Last Friday, July 10, the United States House of Representatives passed H.R. 6 by a vote of 344-77. Pennsylvania Congressmen Barletta, Boyle, Brady, Cartwright, Costello, Dent, Doyle, Fattah, Kelly, Marino, Meehan, Murphy, Pitts, Rothfus, Shuster, and Thompson all supported its passage. The bill, known... Read more

Pharma's specialty drug pricing can torpedo US health care

Thursday, July 2, 2015, 3:39 PM
This past February CVS/Caremark issued a report that forecast a new class of cholesterol drugs, the PCSK-9’s, will cost the U.S. health care system as much as $150 billion a year. Some observers dispute the size of that projected cost, but at the same time the pharma companies are also preparing... Read more

Why pharma can't adapt to the changing health environment

Wednesday, June 24, 2015, 12:48 PM
In nearly every sector of health care, competing companies are acting aggressively to position themselves for prospering in a rapidly changing environment. Consider first the provider segment. Hospital-based systems are gobbling up physician practices to the point where investment bank Credit Suisse... Read more

Trans-Pacific Partnership: Pharma's payoff for Obamacare neutrality

Wednesday, June 17, 2015, 11:08 AM
In 1993 the new Clinton administration decided to make health care reform the signature issue of its first term. Bill Clinton appointed his wife to pilot the initiative, but the entire effort was botched from the get-go. Dubbed Hillarycare by the media, the package was an unwieldy piece of Rube Goldberg... Read more

Health insurers balance long- and short-term moves but can pharma?

Monday, June 8, 2015, 10:41 AM
Commercial success for a new drug brand increasingly depends on whether and, how much, third-party payers will reimburse for it. As more physicians work for large, hospital-based networks, their decision-making role in a drug's success passes to discriminating private insurers and those provider networks... Read more

One week, three lessons for pharma

Friday, May 29, 2015, 12:31 PM
The past week in pharma was one of those times when just setting the news items alongside one another in the proper order can tell someone a lot about the industry. Here are a few lessons to be learned from assembling the jigsaw puzzle. 1. If anyone still doubted it, the emerging markets story is... Read more

When a pharma spokesman advocates value-based pricing

Thursday, May 21, 2015, 4:55 PM
The Forbes columnist and pharma cheerleader, John La Mattina, left Pfizer in 2008 as their R&D head with a $22.6 million package after spending $1 billion of the company's money on an HDL-cholesterol enhancer that never got past the FDA. This week he wrote an item attacking two members of the... Read more

Less research training in medical school? That's actually good

Wednesday, May 13, 2015, 3:41 PM
In Sunday's Health section of the Inquirer, reporter Ilene Raymond Rush interviewed the dean of Temple's medical school, Arthur Feldman. The dean tried to advance an agenda of academic empire building by bemoaning the fact that medical students today receive less research training than in the past... Read more

Which long-term road for GlaxoSmithKline

Thursday, May 7, 2015, 9:35 AM
GlaxoSmithKline (GSK), the British pharmaceutical company with U.S. operations in the Philadelphia area, reported 2015 first quarter earnings this morning. The numbers tell a dismal story. Sales were flat compared to the same period last year, even as revenue from prescription medicines declined... Read more
About this blog

Check Up is a blog for savvy health consumers, covering the latest developments, discoveries, and debates from the Philadelphia area and beyond.

Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Charlotte Sutton Health and Science Editor, Philadelphia Inquirer
Tom Avril Inquirer Staff Writer, heart health and general science
Justin D'Ancona Philly.com
Stacey Burling Inquirer Staff Writer, neuroscience and aging
Marie McCullough Inquirer Staff Writer, cancer and women's health
Don Sapatkin Inquirer Staff Writer, public health, infectious diseases and substance abuse
David Becker, M.D. Board certified cardiologist, Chestnut Hill Temple Cardiology
Michael R. Cohen, R.Ph. President, Institute for Safe Medication Practices
Daniel R. Hoffman, Ph.D. President, Pharmaceutical Business Research Associates
Hooman Noorchashm, M.D., Ph.D. Cardiothoracic surgeon in the Philadelphia area
Amy J. Reed, M.D., Ph.D. Anesthesiologist and Surgical Intensivist in the Philadelphia Area
Latest Health Videos
Also on Philly.com:
letter icon Newsletter